NasdaqGS:CDXSLife Sciences
Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative
Codexis FY 2025 Results: Revenue Rebounds As Profitability Swings Positive In Q4
Codexis (CDXS) closed FY 2025 with a sharp Q4 reset, reporting US$38.9 million in revenue and basic EPS of US$0.11, alongside net income of US$9.6 million, against a trailing twelve month loss of US$44.0 million and a TTM basic EPS loss of US$0.50. The company has seen quarterly revenue move from US$21.5 million in Q4 2024 to US$7.5 million in Q1 2025, US$15.3 million in Q2 2025, US$8.6 million in Q3 2025, and...